APA (7th ed.) Citation

Schaper-Gerhardt, K., Gutzmer, R., Angela, Y., Zimmer, L., Livingstone, E., Schadendorf, D., . . . Becker, J. C. (2024). The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations. European journal of cancer, 202, . https://doi.org/10.1016/j.ejca.2024.113984

Chicago Style (17th ed.) Citation

Schaper-Gerhardt, Katrin, et al. "The RANKL Inhibitor Denosumab in Combination with Dual Checkpoint Inhibition Is Associated with Increased CXCL-13 Serum Concentrations." European Journal of Cancer 202 (2024). https://doi.org/10.1016/j.ejca.2024.113984.

MLA (9th ed.) Citation

Schaper-Gerhardt, Katrin, et al. "The RANKL Inhibitor Denosumab in Combination with Dual Checkpoint Inhibition Is Associated with Increased CXCL-13 Serum Concentrations." European Journal of Cancer, vol. 202, 2024, https://doi.org/10.1016/j.ejca.2024.113984.